Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Citing an unnamed FDA insider, the regulator is in the process of devising a plan to enable clinical testing on a larger scale.
Companies are still developing and refining treatments and preventions for COVID-19, but not all of them are approved or authorized. Here’s a look at the latest COVID-19 news.
A team of researchers at New York University has successfully created synthetic versions of the Hox genes that control biological development in humans.
Cambridge, Massachusetts’ Kendall Square just got a little more crowded following the announcement that life sciences giant Bayer opened its new Research and Innovation Center.
Amarin released disappointing post hoc data from a sub-study of the REDUCE-IT trial, showing that its fish oil-derived Vascepa had little impact on serum biomarkers.
eFFECTOR Therapeutics is pioneering the development of selective translation regulation inhibitors (STRIs), a class of therapies that block the production of disease-driving proteins in cancer.
Entering the second half of 2022, biopharma and life sciences companies from across the globe strengthen their leadership teams with new additions to the c-suite.
The $1.6-billion infusion into its subsidiary is Fujifilm’s latest move to establish a more robust presence in the cell culture manufacturing space.
After the spring reductions in the workforce that left thousands of biotech employees searching for jobs, larger companies are, for the most part, moving forward.
Cellectis shared how its novel immune-evasive universal CAR T cells may potentially deploy large amounts of T-cell product candidates to target multiple malignancies.
Blueprint Medicines announced strategic financing collaborations with Sixth Street and Royalty Pharma for up to $1.25 billion to expand Blueprint’s pipeline and pursue business development opportunities.
Capping off the first half of the year is a flurry of clinical trial wins. BioSpace takes a look at some of the most exciting ones:
